2-(4-benzyloxyphenyl)-2-methylpropionamide | 167762-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-benzyloxyphenyl)-2-methylpropionamide
• 英文别名: alpha,alpha-Dimethyl-4-(phenylmethoxy)benzeneacetamide；2-methyl-2-(4-phenylmethoxyphenyl)propanamide
• CAS: 167762-84-7
• 化学式: C₁₇H₁₉NO₂
• 分子量: 269.343
• InChiKey: NEZDPHRJIDCTSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
  申请人：Shah M. Syed

  公开号：US20070015828A1

  公开（公告）日：2007-01-18

  Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

  提供高度选择性的双重5-羟色胺和去甲肾上腺素再摄取抑制剂。这些化合物具有较低的副作用概况，并可用于治疗多种疾病的组合和产品中，包括抑郁症、纤维肌痛、焦虑症、恐慌障碍、广场恐惧症、创伤后应激障碍、经前期症状障碍、注意力缺陷障碍、强迫症、社交焦虑障碍、广泛性焦虑障碍、自闭症、精神分裂症、肥胖症、厌食症、暴食症、吉尔•德•拉•图雷特综合征、血管运动性潮红、可卡因和酒精成瘾、性功能障碍、边缘人格障碍、纤维肌痛综合征、糖尿病神经病痛、慢性疲劳综合征、疼痛、内脏疼痛、希-德雷格氏综合征、雷诺氏综合征、帕金森病和癫痫。
• Serotonin and norepinephrine reuptake inhibitor and uses thereof
  申请人：Shah M. Syed

  公开号：US20070015824A1

  公开（公告）日：2007-01-18

  Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

  提供了选择性双重抑制素和去甲肾上腺素再摄取抑制素。这些化合物具有较低的副作用，适用于治疗多种疾病的组合和产品，包括抑郁症、纤维肌痛、焦虑症、惊恐障碍、广场恐惧症、创伤后应激障碍、月经前期失调症、注意力缺陷障碍、强迫症、社交焦虑症、广泛性焦虑症、自闭症、精神分裂症、肥胖症、厌食症、贪食症、吉尔·德·拉·图雷特综合征、血管运动性潮红、可卡因和酒精成瘾、性功能障碍、边缘人格障碍、纤维肌痛综合征、糖尿病神经病痛、慢性疲劳综合征、疼痛、希氏-德雷格综合征、雷诺氏综合征、帕金森病和癫痫。
• IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Knoll AG

  公开号：EP0705251A1

  公开（公告）日：1996-04-10
• HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOF
  申请人：Wyeth

  公开号：EP1904434A2

  公开（公告）日：2008-04-02
• Serotonin and norepinephrine reuptake inhibitors and uses thereof
  申请人：Shah M. Syed

  公开号：US20070015791A1

  公开（公告）日：2007-01-18

  Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.